WO2011161970A1 - Anticorps anti-récepteur de pdgf - Google Patents

Anticorps anti-récepteur de pdgf Download PDF

Info

Publication number
WO2011161970A1
WO2011161970A1 PCT/JP2011/003603 JP2011003603W WO2011161970A1 WO 2011161970 A1 WO2011161970 A1 WO 2011161970A1 JP 2011003603 W JP2011003603 W JP 2011003603W WO 2011161970 A1 WO2011161970 A1 WO 2011161970A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
amino acid
seq
acid sequence
pdgfrα
Prior art date
Application number
PCT/JP2011/003603
Other languages
English (en)
Japanese (ja)
Inventor
清水　衛
順裕 丸山
克美 濱田
Original Assignee
株式会社免疫生物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社免疫生物研究所 filed Critical 株式会社免疫生物研究所
Publication of WO2011161970A1 publication Critical patent/WO2011161970A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

L'invention concerne des anticorps contre PDGFRα, et leur utilisation. L'invention concerne spécifiquement un anticorps anti-PDGFRα qui reconnaît une séquence d'acides aminés dans une séquence d'acides aminés de la 106e à la 311e position dans un PDGFRα en tant qu'épitope, un anticorps anti-PDGRFα qui présente une activité de cytotoxicité cellulaire dépendante des anticorps (ADCC) supérieure ou égale à 50 % dans des lymphocytes T, et un anticorps anti-PDGFRα qui présente une activité de cytotoxicité dépendante du complément (CDC) supérieure ou égale à 15 %. L'invention concerne également l'ADN qui code pour les anticorps susmentionnés et une composition pharmaceutique qui comprend les anticorps susmentionnés en tant que composant efficace.
PCT/JP2011/003603 2010-06-24 2011-06-23 Anticorps anti-récepteur de pdgf WO2011161970A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010143397A JP2013177317A (ja) 2010-06-24 2010-06-24 抗ｐｄｇｆ受容体抗体
JP2010-143397 2010-06-24

Publications (1)

Publication Number Publication Date
WO2011161970A1 true WO2011161970A1 (fr) 2011-12-29

Family

ID=45371175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/003603 WO2011161970A1 (fr) 2010-06-24 2011-06-23 Anticorps anti-récepteur de pdgf

Country Status (2)

Country Link
JP (1) JP2013177317A (fr)
WO (1) WO2011161970A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017900A1 (fr) * 2013-08-05 2015-02-12 St. Vincent's Institute Of Medical Research Traitement par anticorps pour maladie associée à la bêta-amyloïde
WO2022226105A1 (fr) * 2021-04-20 2022-10-27 The Trustees Of Columbia University In The City Of New York Antiviraux contre le virus de la rougeole

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011041A1 (fr) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. Composition d'anticorps génétiquement modifié
JP2009501141A (ja) * 2005-06-17 2009-01-15 イムクローン システムズ インコーポレイテッド 転移性骨癌の治療のための受容体アンタゴニスト
WO2009142186A1 (fr) * 2008-05-20 2009-11-26 株式会社カネカ Composition cytotoxique
JP2010500872A (ja) * 2006-08-03 2010-01-14 アストラゼネカ アクチボラグ Ｐｄｇｆｒ−アルファに対して指向性のターゲテッド結合剤およびその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501141A (ja) * 2005-06-17 2009-01-15 イムクローン システムズ インコーポレイテッド 転移性骨癌の治療のための受容体アンタゴニスト
WO2007011041A1 (fr) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. Composition d'anticorps génétiquement modifié
JP2010500872A (ja) * 2006-08-03 2010-01-14 アストラゼネカ アクチボラグ Ｐｄｇｆｒ−アルファに対して指向性のターゲテッド結合剤およびその使用
WO2009142186A1 (fr) * 2008-05-20 2009-11-26 株式会社カネカ Composition cytotoxique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
E TANIGUCHI ET AL.: "PDGFR-A is a Therapeutic Target in Alveolar Rhabdomyosarcoma", ONCOGENE, vol. 27, no. 51, 2008, pages 1 - 18 *
NICK LOIZOS ET AL.: "Targeting the platelet- derived growth facto rreceptor a with a neutralizing human monoclonal antibody inhibits the etgrowth of tumor xenografts: Implications as a potential therapeutic target", MOL CANCER THER, vol. 4, no. 3, 2005, pages 369 - 379 *
PEGGY STOCK ET AL.: "Platelet-derived growth factor receptor-a: a novel therapeutic target in human hepatocellular cancer", MOL CANCER THER, vol. 6, no. 7, 2007, pages 1932 - 1941 *
ROBERT L. SHIELDS ET AL.: "Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody- dependent Cellular Toxicity", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 30, 2002, pages 26733 - 26740 *
TOYOHIDE SHINKAWA ET AL.: "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 5, 2003, pages 3466 - 3473 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017900A1 (fr) * 2013-08-05 2015-02-12 St. Vincent's Institute Of Medical Research Traitement par anticorps pour maladie associée à la bêta-amyloïde
US9908933B2 (en) 2013-08-05 2018-03-06 St. Vincent's Institute Of Medical Research Antibody therapy for amyloid beta disease
WO2022226105A1 (fr) * 2021-04-20 2022-10-27 The Trustees Of Columbia University In The City Of New York Antiviraux contre le virus de la rougeole

Also Published As

Publication number Publication date
JP2013177317A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
JP6847037B2 (ja) 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
JP6060073B2 (ja) Ｃｄ１２２に対する抗体
JP2021524250A (ja) Ｐｓｍａ結合剤及びその使用
JP2022515318A (ja) 抗体及びその用途
KR20210040827A (ko) 항 tigit 항체 및 그 용도
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
WO2019091449A1 (fr) Anticorps cd96, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
KR20210137477A (ko) 이중기능성 융합 단백질 및 그것의 제약학적 용도
WO2020114479A1 (fr) Molécule de protéine multispécifique
AU2017379382A1 (en) Anti-CD3 Antibody and Molecules Comprising the Antibody
TWI821474B (zh) Ｃｄ３抗體及其藥物用途
TWI745670B (zh) 抗cd27抗體、其抗原結合片段及其醫藥用途
CN110770252A (zh) 抗p53抗体
CN115812081A (zh) 抗ctla-4抗体及其用途
CN116249717A (zh) 识别分拣蛋白的抗体
CN116769034B (zh) 抗cd73抗体或其抗原片段及其应用
TWI801350B (zh) 自體免疫疾病治療用抗體及其製造方法
WO2011161970A1 (fr) Anticorps anti-récepteur de pdgf
JP6872756B2 (ja) 抗Ｍｙｌ９抗体
RU2809746C2 (ru) Гуманизированное моноклональное антитело против vegf
RU2790326C2 (ru) Анти-сd3-антитело и молекула, содержащая это антитело
JP7384668B2 (ja) 細胞傷害性ｔ細胞枯渇用組成物
WO2022078424A1 (fr) Anticorps anti-trop-2, fragment de liaison à l'antigène de celui-ci ou mutant de celui-ci, et utilisation médicale associée
JP2024509369A (ja) 抗ｐｄ－ｌ１抗体及びその使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11797858

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11797858

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP